Reduction of toxicity in brachytherapy using a new technique.

Abstract

PURPOSE:

The purpose of the study was to elucidate the usefulness of a dose evaluation method for reducing late genitourinary (GU) toxicity in high-dose-rate brachytherapy (HDR-BT) of prostate cancer.

METHODS AND MATERIALS:

GU toxicity was scored in accordance with the Common Terminology Criteria for Adverse Events version 4.0. The prostatic urethra was divided into three segments (base = B, midgland = M, apex = A), which were subclassified into seven subgroups (B, M, A, BM, BA, MA, BMA) using a D10% color map of the urethra. Significance testing was conducted on urethral D0.1% and D10% among the seven subgroups. Grade < 2 GU toxicity was also implemented.

RESULTS:

Data of 174 patients with localized prostate cancer treated with HDR-BT combined with external beam radiotherapy between November 2011 and July 2014 were analyzed retrospectively. Median age was 74 (53-84) years, and median followup period was 44 (6-69) months. The number of Grade < 2 and Grade ≥ 2 toxicity was significantly different in the M subgroup than in the other subgroups (p < 0.05), suggesting increased radioresistance in the midgland urethra.

CONCLUSIONS:

A high-dose-area evaluation method using a urethral D10% color map may be helpful in reducing late GU toxicity in HDR-BT for prostate cancer.

• Authors: Yuji Miyazaki, Yukiho Takenaka, Yasutaka Noda, Nobuyuki Kawai, Takanori Yoshikawa, Takahito Wakamiya, Isao Hara, Tetsuo Sonomura
• Journal: Brachytherapy (Brachytherapy) 2021 Jul-Aug Vol. 20 Issue 4 Pg. 866-872 ISSN: 1873-1449 [Electronic] United States
• PMID: 33896731 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Topics

• Aged
• Brachytherapy (methods)
• Humans
• Male
• Prostatic Neoplasms (radiotherapy)
• Radiation Injuries
• Radiotherapy Dosage
• Retrospective Studies
• Urogenital System